Benzinga · Sep 23, 2026
Needham Reiterates Buy on Absci, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $11 price target.
AB
NASDAQ · ABSI
Absci Corporation
Healthcare · Biotechnology
$9.74
Down-$0.61 (-5.85%)
Updated Sep 26, 2026, 1:07 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 412.02M
- P/E ratio
- -3.44
- Dividend yield
- 0.00%
- 52-week range
- $2.24 – $12.06
- Volume
- 3.21M
- Avg. volume
- 3.49M
Price performance
ABSI price history
1M range · 20 trading sessions · Daily adjusted prices
ABSI closed at $9.74 after 20 trading sessions, up 11.83% for the selected period.
- Last close
- $9.74
- Period change
- +11.83%
- Period low
- $7.94
- Period high
- $10.71
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 25, 2026 | $10.49 | $10.50 | $9.68 | $9.74 | 3.21M |
| Sep 24, 2026 | $9.55 | $10.39 | $9.30 | $10.345 | 3.39M |
| Sep 23, 2026 | $10.51 | $10.62 | $9.47 | $9.745 | 4.72M |
| Sep 22, 2026 | $10.00 | $11.255 | $9.75 | $10.71 | 8.37M |
| Sep 21, 2026 | $10.06 | $10.15 | $9.50 | $9.82 | 4.56M |
| Sep 18, 2026 | $9.27 | $9.74 | $9.08 | $9.65 | 7.73M |
| Sep 17, 2026 | $8.295 | $9.83 | $8.285 | $9.27 | 8.67M |
| Sep 16, 2026 | $8.02 | $8.20 | $7.865 | $8.04 | 2.61M |
| Sep 15, 2026 | $8.055 | $8.07 | $7.79 | $7.94 | 2.34M |
| Sep 14, 2026 | $8.03 | $8.25 | $8.02 | $8.09 | 3M |
| Sep 11, 2026 | $8.42 | $8.57 | $8.11 | $8.21 | 1.97M |
| Sep 10, 2026 | $8.375 | $8.56 | $8.0198 | $8.24 | 3.09M |
| Sep 9, 2026 | $8.89 | $9.02 | $8.625 | $8.65 | 2.03M |
| Sep 8, 2026 | $8.82 | $9.10 | $8.57 | $8.91 | 2.51M |
| Sep 4, 2026 | $8.69 | $9.03 | $8.65 | $8.82 | 2.15M |
| Sep 3, 2026 | $8.91 | $8.9953 | $8.55 | $8.80 | 2.75M |
| Sep 2, 2026 | $8.90 | $9.23 | $8.36 | $8.80 | 2.95M |
| Sep 1, 2026 | $8.85 | $9.08 | $8.711 | $8.84 | 3.24M |
| Aug 31, 2026 | $8.67 | $9.09 | $8.6198 | $9.04 | 5.26M |
| Aug 28, 2026 | $9.202 | $9.30 | $8.60 | $8.71 | 2.51M |
Latest ABSI news
The latest Smart Investors Daily articles mentioning ABSI.
Stock researchCompany · Overview
ABSI research
Overview
Company profile and research snapshot.
Company profile
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.00
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Needham | Buy | — |
| Sep 9, 2026 | LifeSci Capital | Outperform | — |
| Sep 8, 2026 | BTIG | Buy | — |
| Aug 12, 2026 | Needham | Buy | — |
| Aug 12, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 22, 2026
Absci (ABSI) Stock Looks Expensive Against Its Book Value
Absci has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$9.82 level is supported by the company’s book value. For anyone looking at the stock today, the key issue is how that accounting base stacks up against the recent share price performance. Over the past 3 years, Absci has delivered a very large share price gain, which raises the question of how much of that move is mirrored in the company’s underlying net assets. The business model...
SeekingAlpha · Sep 16, 2026
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci Corporation (ABSI) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 7:45 AM EDTCompany ParticipantsSean McClain - Founder,...
Yahoo · Sep 12, 2026
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom. Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% since its February 2026 initial public offering, while Absci Corporation (NASDAQ:ABSI)’s stock has more than doubled so far in 2026. Switzerland’s […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
